上海医药集团股份有限公司 关于阿立哌唑片获得菲律宾药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属上海上药中西制药有限公司（以下简称"上药中西"）生产的阿立哌唑片（以 下简称"该药品"）收到菲律宾食品药品监督管理局颁发的药品注册证书，该药 品获得批准上市。 一、药品基本情况 药品名称：阿立哌唑片 注册证号：DRP-16802 二、药品相关的信息 证券代码：601607 证券简称：上海医药 编号：临2025-082 三、药品市场竞争情况 截至本公告日，在菲律宾境内阿立哌唑片主要有 OTSUKA PHARM，ZYDUS PHILS. INC.，MULTICARE PHARM 等其他 5 家销售商。 IQVIA 数据库显示，2024 年菲律宾市场阿立哌唑片（10 mg）合计销售额为 239 万美元。 四、对上市公司影响及风险提示 本次阿立哌唑片（10 mg）获得菲律宾食品药品监督管理局的药品注册批文， 标志着公司具备了在菲律宾市场销售该药 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd. (referred to as "Shiyou Zhongxi"), has received a drug registration certificate from the Philippines Food and Drug Administration for Aripiprazole Tablets, which have been approved for market launch [1] Group 1 - The drug Aripiprazole is an antipsychotic medication primarily used for the treatment of schizophrenia and manic episodes of bipolar disorder, and it can also be used as an adjunct treatment for depression [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Chinese-Western Medicine Co., Ltd., has received a drug registration certificate from the Philippines Food and Drug Administration for Aripiprazole tablets, which have been approved for market launch [1] Group 1 - The drug Aripiprazole is an antipsychotic medication primarily used for the treatment of schizophrenia and manic episodes of bipolar disorder, and it can also be used as an adjunct treatment for depression [1]

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has received a drug registration certificate from the Philippines Food and Drug Administration for Aripiprazole tablets, allowing the product to be marketed in the Philippines [1] Company Summary - Aripiprazole tablets are an antipsychotic medication primarily used for the treatment of schizophrenia and manic episodes of bipolar disorder, and can also serve as an adjunct treatment for depression [1] - The company incurred approximately 50,000 yuan in registration-related expenses for the product's market entry in the Philippines [1] Market Summary - The total sales revenue for Aripiprazole tablets (10 mg) in the Philippines is projected to be 2.39 million USD in 2024 [1]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因依賴該等內容而引致之任何損失承擔任何責任。 中國上海，2025年9月9日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明先生；非執 行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先生、王忠先生及萬鈞女 士。 Shanghai Pharmaceuticals Holding Co., Ltd.* ( ) 於中華人民共和國註冊成立的股份有限公司 (股份代碼: 02607) 關連交易 擬收購財務公司 10%股權 最新進展 茲提述上海醫藥集團股份有限公司（「本公司」）日期為2025年7月26日的公告（「該公 告」），內容有關擬訂立之股份轉讓協議，據此本公司擬議收購而上實東灘擬議出售財務公 司10%股權。除本公告另有界定外，本公告所用詞彙與該公告所界定者具有相同涵義。 董事會欣然宣佈，本公司已於2025年9月8日與上實東灘按該公告所載的主要條款簽署了股份 轉讓協議。 除上文所披露者外，該公告的所有其他資料維持不變。 承董 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase of over 20% compared to the benchmark index within six months [9][13]. Core Views - The company demonstrated steady operational progress with strong cost control capabilities, reporting a revenue of 1415.93 billion yuan for H1 2025, a 1.56% increase year-on-year. The net profit attributable to shareholders reached 44.59 billion yuan, marking a significant increase of 51.56% [3][4]. - The pharmaceutical commercial segment showed growth driven by innovative business models, with sales from innovative drug business and health equipment reaching 242 billion yuan and 225.7 billion yuan respectively, reflecting growth rates of 22.6% and 18.8% [5][6]. - The company has a solid pipeline for new drug development, with several innovative drugs progressing through clinical trials, including I001 for hypertension and B007 for severe myasthenia gravis [6][8]. Financial Summary - For H1 2025, the gross margin was 10.55%, a decrease of 1.05 percentage points, while the net profit margin increased to 3.15%, up by 1.04 percentage points. The company reported a net cash flow from operating activities of 9.89 billion yuan, a substantial increase of 91.98% [4][3]. - Revenue projections for 2025-2027 are estimated at 2866.66 billion yuan, 3014.40 billion yuan, and 3171.40 billion yuan respectively, with net profits expected to be 57.01 billion yuan, 55.38 billion yuan, and 60.74 billion yuan [9][11].

Group 1 - The company Shanghai Pharmaceutical Group Co., Ltd. announced that its subsidiary, Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd., received a notification from the National Medical Products Administration approving the supplementary application for the drug Dihydroxypropyl Theophylline Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1][2] - The drug Dihydroxypropyl Theophylline Injection is indicated for bronchial asthma, wheezing bronchitis, and obstructive pulmonary emphysema, and it was developed by Eisai Co., Ltd. and launched in Japan in October 1952 [2] - As of the announcement date, the company has invested approximately RMB 3.05 million in research and development for this drug [2] Group 2 - The approval of the drug's consistency evaluation is expected to enhance its market share and competitiveness, as products that pass this evaluation will receive greater support in medical insurance payments and procurement by medical institutions [2] - The total procurement amount for Dihydroxypropyl Theophylline Injection (2ml:0.3g) in hospitals in mainland China for 2024 is reported to be RMB 9.737 million [2]

Group 1: Company Announcements - Heng Rui Medicine has received the clinical trial approval notice for HRS-4729 injection, a self-developed peptide drug targeting GLP-1R, GIPR, and GCGR receptors, with no similar products approved in the market [1] - Hubei Yihua has successfully launched its 200,000 tons/year caustic soda project, aimed at upgrading its chlor-alkali chemical industry and enhancing market competitiveness [2] - Ji Min Health announced that its shareholder, Shuangge Group, plans to reduce its stake by up to 3%, equating to a maximum of 15.75 million shares [3] - China Shipbuilding intends to absorb and merge with China Shipbuilding Industry Corporation through a share exchange, with the latter's A-shares set to be delisted on September 5, 2025 [4] - Changfei Fiber reported that its shareholder, Changjiang Communication, plans to reduce its stake by up to 0.15%, totaling no more than 1.1 million shares [5] Group 2: Strategic Collaborations and Developments - Beijing Lier has signed a strategic cooperation agreement with SenseTime and Xiwang Technology to explore AI computing power collaboration and related applications [6] - Junsheng Electronics is collaborating with leading clients like Zhiyuan Robotics, having achieved bulk supply of customized main control boards and various sensors [7][8] - Guoxin Technology has successfully tested a new generation of high-performance chips for automotive electronic BLDC motor control, aimed at addressing the MCU chip shortage in the automotive sector [9] Group 3: Other Corporate Actions - Guoguang Chain's actual controller plans to reduce their stake by up to 2.99%, totaling a maximum of 12.506 million shares [10] - Zhonghuan Hailu has terminated its control change plan, with its stock set to resume trading on September 5, 2025 [11] - Various companies have reported significant project wins, including Ningbo Construction winning contracts worth 1.117 billion yuan [12]

Group 1 - The core point of the article is that Shanghai Pharmaceuticals announced the approval of its dihydroxypropyl theophylline injection by the National Medical Products Administration, indicating that the drug has passed the consistency evaluation of quality and efficacy for generic drugs [2] Group 2 - The drug is produced by Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceuticals [2] - The approval signifies a significant milestone for the company in expanding its product portfolio in the pharmaceutical market [2] - The consistency evaluation is crucial for ensuring that generic drugs meet the same standards as their branded counterparts, which can enhance market competitiveness [2]